Patient Controlled Intrathecal Analgesia With Bupivacaine for Chronic Low Back Pain
| Status: | Completed |
|---|---|
| Conditions: | Chronic Pain, Chronic Pain |
| Therapuetic Areas: | Musculoskeletal |
| Healthy: | No |
| Age Range: | 31 - 90 |
| Updated: | 6/16/2018 |
| Start Date: | May 2016 |
| End Date: | December 2017 |
Randomized, Double Blind, Cross Over Study Comparing Effectiveness of Traditional Opioids Versus Opioids in Admixture With Bupivacaine Upon Self-administration of Boluses Via a Personal Therapy Manager (PTM) in Intrathecal Pumps
The purpose of this study is to determine whether the local anesthetic bupivacaine delivered
intrathecally in small doses via PTM self-administered boluses significantly improves the
breakthrough pain and functional status of patients with chronic intractable pain who are
managed with an intrathecal drug delivery system.
intrathecally in small doses via PTM self-administered boluses significantly improves the
breakthrough pain and functional status of patients with chronic intractable pain who are
managed with an intrathecal drug delivery system.
Methodology /Technical Approach:
Seventeen patients who are already using SynchroMed II pump containing an admixture of
bupivacaine and an opioid and using PTM doses will receive Solution A during the first week
of the study and will be crossed over to Solution B during the second week of the study.
Solution A and Solution B would consist of either the patient's usual intrathecal opioid with
bupivacaine at the same concentrations or the usual patient's intrathecal opioid at the same
concentration but without bupivacaine. Only the Investigational Pharmacy at University
Hospitals Case Medical Center (UHCMC) would be aware of the contents of Solution A and
Solution B. Patients and study personnel in the Pain Medicine Division would be blinded to
the solution content. The sequence of pump refills will be as follows:
- Week I: Patients will have the intrathecal pumps refilled with 10 milliliters of a
Solution A or B, after removal of residual volume of baseline solution.
- Week II: IT pump will be filled with 10 ml of Solution A or B (whichever solution
subject did not receive Week 1), after removal of residual volume from Week I.
Both patients and the evaluating physician will be blinded. In order to accomplish this, only
the central compounding (investigational) pharmacy at UHCMC would make two solutions labeled:
A or B respectively. Study subjects will be randomized and randomization order will be held
at the pharmacy that will supply the medication. Patients will be kept on each solution for
one week. Data will be collected daily
Primary outcome measures will include 0-10 numerical rating scale (NRS) or Visual Analogue
Scale (VAS) both immediately before and within 30 minutes after a PTM bolus. Patients will be
provided with a diary to record pain scores just before a PTM bolus and the lowest pain score
within half an hour after a PTM bolus. Only 5 recording per day on days 3-7 and 10-14 will be
available on the diary—thus patients would record pain scores only before and after the first
5 PTM boluses. Only the scores before and after the first 3 successful PTM boluses would be
considered. Successful PTM activations would be determined by review of the patient PTM diary
and the internal log from the intrathecal drug delivery system. Each recording on the PTM
diary would be time matched to the successful PTM activation code in the internal log. This
will obviate any potential mis-administered bolus whereby the patient does not activate the
bolus device appropriately. Secondary outcome measures will include average NRS pain scores
for the week, functional capacity as evaluated by the Oswestry disability index (ODI) scores,
Global Impression of Change and painDETECT. Other relevant data such as number of boluses
used and paresthetic sensation post bolus (if felt)/patient guess of blinding arm would be
recorded.
Seventeen patients who are already using SynchroMed II pump containing an admixture of
bupivacaine and an opioid and using PTM doses will receive Solution A during the first week
of the study and will be crossed over to Solution B during the second week of the study.
Solution A and Solution B would consist of either the patient's usual intrathecal opioid with
bupivacaine at the same concentrations or the usual patient's intrathecal opioid at the same
concentration but without bupivacaine. Only the Investigational Pharmacy at University
Hospitals Case Medical Center (UHCMC) would be aware of the contents of Solution A and
Solution B. Patients and study personnel in the Pain Medicine Division would be blinded to
the solution content. The sequence of pump refills will be as follows:
- Week I: Patients will have the intrathecal pumps refilled with 10 milliliters of a
Solution A or B, after removal of residual volume of baseline solution.
- Week II: IT pump will be filled with 10 ml of Solution A or B (whichever solution
subject did not receive Week 1), after removal of residual volume from Week I.
Both patients and the evaluating physician will be blinded. In order to accomplish this, only
the central compounding (investigational) pharmacy at UHCMC would make two solutions labeled:
A or B respectively. Study subjects will be randomized and randomization order will be held
at the pharmacy that will supply the medication. Patients will be kept on each solution for
one week. Data will be collected daily
Primary outcome measures will include 0-10 numerical rating scale (NRS) or Visual Analogue
Scale (VAS) both immediately before and within 30 minutes after a PTM bolus. Patients will be
provided with a diary to record pain scores just before a PTM bolus and the lowest pain score
within half an hour after a PTM bolus. Only 5 recording per day on days 3-7 and 10-14 will be
available on the diary—thus patients would record pain scores only before and after the first
5 PTM boluses. Only the scores before and after the first 3 successful PTM boluses would be
considered. Successful PTM activations would be determined by review of the patient PTM diary
and the internal log from the intrathecal drug delivery system. Each recording on the PTM
diary would be time matched to the successful PTM activation code in the internal log. This
will obviate any potential mis-administered bolus whereby the patient does not activate the
bolus device appropriately. Secondary outcome measures will include average NRS pain scores
for the week, functional capacity as evaluated by the Oswestry disability index (ODI) scores,
Global Impression of Change and painDETECT. Other relevant data such as number of boluses
used and paresthetic sensation post bolus (if felt)/patient guess of blinding arm would be
recorded.
Inclusion Criteria
- Age more than 30 years implanted with an intrathecal drug delivery device.
- Intrathecal pump patients on stable dose for the last 3 months.
- Using on average more than 2 and less than 10 PTM doses per day
- Intrathecal medication admixture consisting of bupivacaine and another opioid
(fentanyl or hydromorphone or morphine)
Exclusion Criteria
- Using 10 or more PTM bolus doses per day or 2 or less PTM bolus doses per day
- Pending litigation or worker compensation claim
- Any recent (less than 3 month) procedures in spine (surgeries) or catheter
adjustments.
- Recent pump dose adjustment within the past 3 months
- Pumps with medications other than bupivacaine/opioid combination.
- Pregnant or breast feeding
We found this trial at
1
site
Click here to add this to my saved trials
